<p>Nuvation Bio Inc.（纽约证券交易所代码：NUVB - 获取免费报告）在周一交易前股价跳空下跌。该股此前收于 1.73 美元，但开盘价为 1.66 美元。Nuvation Bio 的股票最后交易价格为 1.79 美元，成交量为 3,097,573 股。</p>
<h2>华尔街分析师预测增长</h2>
<p>NUVB 近期成为多份研究报告的主题。HC Wainwright 在 3 月 10 日的报告中将 Nuvation Bio 的目标股价从 11.00 美元下调至 10.00 美元，并对该股给予 “买入” 评级。JMP 证券在 6 月 2 日的研究报告中重申了 “市场表现优于大盘” 的评级，并对 Nuvation Bio 的股票设定了 6.00 美元的目标价。Citizens Jmp 在 4 月 23 日的报告中开始覆盖 Nuvation Bio 的股票，给予 “市场表现优于大盘” 的评级，并设定 6.00 美元的目标价。Wedbush 在 6 月 11 日的报告中重申了 “表现优于大盘” 的评级，并对 Nuvation Bio 的股票设定了 5.00 美元的目标价。最后，花旗集团在 4 月 23 日的研究报告中开始覆盖 Nuvation Bio，给予该股 “表现优于大盘” 的评级。一位股票研究分析师对该股给予了卖出评级，五位分析师给予买入评级，一位分析师给予强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 7.83 美元。</p>
<p><strong>查看我们关于 NUVB 的最新研究报告</strong></p>
<h2>Nuvation Bio 股票表现</h2>
<p>该公司的 50 日移动平均线为 2.15 美元，200 日移动平均线为 2.29 美元。该公司的市值为 6.1417 亿美元，市盈率为-0.83，贝塔值为 1.37。</p>
<p>Nuvation Bio（纽约证券交易所代码：NUVB - 获取免费报告）最近在 5 月 7 日发布了季度财报。该公司报告每股收益（EPS）为-0.16 美元，符合分析师的共识预期（-0.16 美元）。该公司季度收入为 308 万美元，而共识预期为 42 万美元。卖方分析师预计 Nuvation Bio Inc.在当前财政年度将发布-0.36 的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，首席执行官 David Hung 在 4 月 4 日的交易中购买了 200,000 股该股票。该股票的平均购买成本为每股 1.66 美元，总交易额为 332,000.00 美元。交易完成后，首席执行官现在直接持有 58,481,054 股公司股票，价值 97,078,549.64 美元。这笔交易代表了他们持股比例的 0.34% 的增加。该购买在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Dongfang Liu 在 5 月 2 日的交易中出售了 20,000 股公司的股票。该股票的平均售价为每股 2.50 美元，总交易额为 50,000.00 美元。交易完成后，该内部人士现在直接持有 12,000 股公司股票，价值 30,000 美元。这笔交易代表了他们持股比例的 62.50% 的减少。该出售的披露信息可以在这里找到。内部人士持有公司 29.93% 的股票。</p>
<h2>机构投资者对 Nuvation Bio 的看法</h2>
<p>几家机构投资者最近调整了对 NUVB 的持股。Wealth Enhancement Advisory Services LLC 在第四季度购买了 Nuvation Bio 的新头寸，价值约 27,000 美元。Forum Financial Management LP 在第四季度购买了 Nuvation Bio 的新头寸，价值 29,000 美元。Cerity Partners LLC 在第四季度购买了 Nuvation Bio 的新头寸，价值 31,000 美元。Firethorn Wealth Partners LLC 在第一季度收购了 Nuvation Bio 的新股份，价值 35,000 美元。最后，Russell Investments Group Ltd.在第四季度将其在 Nuvation Bio 的持股增加了 15,183.7%。Russell Investments Group Ltd.现在持有 15,895 股公司股票，价值 42,000 美元，此前在上个季度又购买了 15,791 股。机构投资者和对冲基金持有公司 61.67% 的股票。</p>
<h2>关于 Nuvation Bio</h2>
<p>（获取免费报告）</p>
<p>Nuvation Bio Inc.是一家临床阶段的生物制药公司，专注于肿瘤治疗候选药物的开发。该公司的主要产品候选药物是 NUV-868，一种 BD2 选择性口服小分子 BET 抑制剂，能够表观遗传学调节控制肿瘤生长和分化的蛋白质，包括 c-myc 等癌基因；NUV-1156，一种 AR 结合剂 Xtandi，针对晚期前列腺癌，具有进入通常通过手术前列腺切除术治疗的早期阶段的潜力；以及药物 - 药物结合平台（DDC），该平台利用抗癌疗法药物结合类中的新型治疗方法，将抗癌药物输送到癌细胞，同时还有 NUV-1176，一种 PARP 抑制剂，针对 ER+ 乳腺癌和卵巢癌。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Nuvation Bio 更好</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>AST SpaceMobile 的明星正在上升：在它仍然便宜的时候入手！</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>四只具有动能和增长空间的优质成长股</li>
<li>什么是上海证券交易所综合指数？</li>
<li>Meta 和 Eli Lilly 会引发下一个股票拆分热潮吗？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Nuvation Bio 吗？</h2>
<p>在你考虑 Nuvation Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Nuvation Bio 并不在名单上。</p>
<p>虽然 Nuvation Bio 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NUVB

<p>Nuvation Bio（纽约证券交易所代码：NUVB）股价在周一交易前从 1.73 美元跳空下跌至 1.66 美元，最后交易价格为 1.79 美元。分析师的评级不一，HC Wainwright 将其目标价从 11 美元下调至 10 美元，而 JMP Securities 维持 6 美元的目标价。该公司报告的季度每股收益为（0.16 美元），收入为 308 万美元。首席执行官 David Hung 以 1.66 美元购买了 200,000 股，增加了他的持股比例。机构投资者持有 61.67% 的股份，平均目标价为 7.83 美元</p>

<p>Nuvation Bio Inc. (NYSE:NUVB - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $1.73, but opened at $1.66. Nuvation Bio shares last traded at $1.79, with a volume of 3,097,573 shares traded.</p>
<div class="lb-trans"><p>Nuvation Bio Inc.（纽约证券交易所代码：NUVB - 获取免费报告）在周一交易前股价跳空下跌。该股此前收于 1.73 美元，但开盘价为 1.66 美元。Nuvation Bio 的股票最后交易价格为 1.79 美元，成交量为 3,097,573 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>NUVB has been the topic of a number of recent research reports. HC Wainwright cut their price target on shares of Nuvation Bio from $11.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, March 10th. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $6.00 target price on shares of Nuvation Bio in a research note on Monday, June 2nd. Citizens Jmp started coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued a &#34;mkt outperform&#34; rating and a $6.00 target price on the stock. Wedbush restated an &#34;outperform&#34; rating and set a $5.00 price target on shares of Nuvation Bio in a report on Wednesday, June 11th. Finally, Citigroup assumed coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They issued an &#34;outperform&#34; rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $7.83.</p>
<div class="lb-trans"><p>NUVB 近期成为多份研究报告的主题。HC Wainwright 在 3 月 10 日的报告中将 Nuvation Bio 的目标股价从 11.00 美元下调至 10.00 美元，并对该股给予 “买入” 评级。JMP 证券在 6 月 2 日的研究报告中重申了 “市场表现优于大盘” 的评级，并对 Nuvation Bio 的股票设定了 6.00 美元的目标价。Citizens Jmp 在 4 月 23 日的报告中开始覆盖 Nuvation Bio 的股票，给予 “市场表现优于大盘” 的评级，并设定 6.00 美元的目标价。Wedbush 在 6 月 11 日的报告中重申了 “表现优于大盘” 的评级，并对 Nuvation Bio 的股票设定了 5.00 美元的目标价。最后，花旗集团在 4 月 23 日的研究报告中开始覆盖 Nuvation Bio，给予该股 “表现优于大盘” 的评级。一位股票研究分析师对该股给予了卖出评级，五位分析师给予买入评级，一位分析师给予强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 7.83 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on NUVB</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NUVB 的最新研究报告</strong></p>
</div><h2>Nuvation Bio Stock Performance</h2>
<div class="lb-trans"><h2>Nuvation Bio 股票表现</h2>
</div><p>The company has a 50-day moving average of $2.15 and a 200 day moving average of $2.29. The firm has a market cap of $614.17 million, a P/E ratio of -0.83 and a beta of 1.37.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 2.15 美元，200 日移动平均线为 2.29 美元。该公司的市值为 6.1417 亿美元，市盈率为-0.83，贝塔值为 1.37。</p>
</div><p>Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16). The company had revenue of $3.08 million for the quarter, compared to the consensus estimate of $0.42 million. Sell-side analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Nuvation Bio（纽约证券交易所代码：NUVB - 获取免费报告）最近在 5 月 7 日发布了季度财报。该公司报告每股收益（EPS）为-0.16 美元，符合分析师的共识预期（-0.16 美元）。该公司季度收入为 308 万美元，而共识预期为 42 万美元。卖方分析师预计 Nuvation Bio Inc.在当前财政年度将发布-0.36 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO David Hung acquired 200,000 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was purchased at an average cost of $1.66 per share, for a total transaction of $332,000.00. Following the completion of the transaction, the chief executive officer now directly owns 58,481,054 shares in the company, valued at $97,078,549.64. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dongfang Liu sold 20,000 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $2.50, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now directly owns 12,000 shares in the company, valued at $30,000. This trade represents a 62.50% decrease in their position. The disclosure for this sale can be found here. Insiders own 29.93% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 David Hung 在 4 月 4 日的交易中购买了 200,000 股该股票。该股票的平均购买成本为每股 1.66 美元，总交易额为 332,000.00 美元。交易完成后，首席执行官现在直接持有 58,481,054 股公司股票，价值 97,078,549.64 美元。这笔交易代表了他们持股比例的 0.34% 的增加。该购买在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Dongfang Liu 在 5 月 2 日的交易中出售了 20,000 股公司的股票。该股票的平均售价为每股 2.50 美元，总交易额为 50,000.00 美元。交易完成后，该内部人士现在直接持有 12,000 股公司股票，价值 30,000 美元。这笔交易代表了他们持股比例的 62.50% 的减少。该出售的披露信息可以在这里找到。内部人士持有公司 29.93% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Nuvation Bio</h2>
<div class="lb-trans"><h2>机构投资者对 Nuvation Bio 的看法</h2>
</div><p>Several institutional investors have recently modified their holdings of NUVB. Wealth Enhancement Advisory Services LLC bought a new position in Nuvation Bio in the fourth quarter valued at approximately $27,000. Forum Financial Management LP bought a new position in shares of Nuvation Bio in the 4th quarter worth $29,000. Cerity Partners LLC bought a new position in shares of Nuvation Bio in the 4th quarter worth $31,000. Firethorn Wealth Partners LLC acquired a new stake in shares of Nuvation Bio during the first quarter worth $35,000. Finally, Russell Investments Group Ltd. increased its holdings in Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after purchasing an additional 15,791 shares during the last quarter. Institutional investors and hedge funds own 61.67% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对 NUVB 的持股。Wealth Enhancement Advisory Services LLC 在第四季度购买了 Nuvation Bio 的新头寸，价值约 27,000 美元。Forum Financial Management LP 在第四季度购买了 Nuvation Bio 的新头寸，价值 29,000 美元。Cerity Partners LLC 在第四季度购买了 Nuvation Bio 的新头寸，价值 31,000 美元。Firethorn Wealth Partners LLC 在第一季度收购了 Nuvation Bio 的新股份，价值 35,000 美元。最后，Russell Investments Group Ltd.在第四季度将其在 Nuvation Bio 的持股增加了 15,183.7%。Russell Investments Group Ltd.现在持有 15,895 股公司股票，价值 42,000 美元，此前在上个季度又购买了 15,791 股。机构投资者和对冲基金持有公司 61.67% 的股票。</p>
</div><h2>About Nuvation Bio</h2>
<div class="lb-trans"><h2>关于 Nuvation Bio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.</p>
<div class="lb-trans"><p>Nuvation Bio Inc.是一家临床阶段的生物制药公司，专注于肿瘤治疗候选药物的开发。该公司的主要产品候选药物是 NUV-868，一种 BD2 选择性口服小分子 BET 抑制剂，能够表观遗传学调节控制肿瘤生长和分化的蛋白质，包括 c-myc 等癌基因；NUV-1156，一种 AR 结合剂 Xtandi，针对晚期前列腺癌，具有进入通常通过手术前列腺切除术治疗的早期阶段的潜力；以及药物 - 药物结合平台（DDC），该平台利用抗癌疗法药物结合类中的新型治疗方法，将抗癌药物输送到癌细胞，同时还有 NUV-1176，一种 PARP 抑制剂，针对 ER+ 乳腺癌和卵巢癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Nuvation Bio</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Top 4 Growth Stocks With Momentum and Room to Run</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Could Meta and Eli Lilly Trigger the Next Stock Split Boom?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Nuvation Bio 更好</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>AST SpaceMobile 的明星正在上升：在它仍然便宜的时候入手！</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>四只具有动能和增长空间的优质成长股</li>
<li>什么是上海证券交易所综合指数？</li>
<li>Meta 和 Eli Lilly 会引发下一个股票拆分热潮吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nuvation Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Nuvation Bio 吗？</h2>
</div><p>Before you consider Nuvation Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Nuvation Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Nuvation Bio 并不在名单上。</p>
</div><p>While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nuvation Bio 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nuvation Bio（NYSE:NUVB）股价跳空低开 - 现在是卖出的时候吗？